These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 24929497)

  • 1. Herceptin cardiotoxicity and delayed breast reconstruction surgery.
    Allouni A; Wharton E; Collin T
    J Plast Reconstr Aesthet Surg; 2014 Nov; 67(11):e273-4. PubMed ID: 24929497
    [No Abstract]   [Full Text] [Related]  

  • 2. Mastectomy and reconstruction in stage IV breast cancer: a survey of UK breast and plastic surgeons.
    Durrant CA; Khatib M; Macneill F; James S; Harris P
    Breast; 2011 Aug; 20(4):373-9. PubMed ID: 21376594
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pertuzumab-induced cardiotoxicity: safety compared with trastuzumab.
    Sendur MA; Aksoy S; Altundag K
    Future Oncol; 2015; 11(1):13-5. PubMed ID: 25572781
    [No Abstract]   [Full Text] [Related]  

  • 4. Adjuvant! Online as a decision-making tool in early breast cancer--a UK national survey.
    Agarwal V; O'Neill P
    Clin Oncol (R Coll Radiol); 2011 Mar; 23(2):159-60. PubMed ID: 21112194
    [No Abstract]   [Full Text] [Related]  

  • 5. Cardiotoxicity: trastuzumab and cancer survivors.
    Patanè S
    Int J Cardiol; 2014 Dec; 177(2):554-6. PubMed ID: 25205483
    [No Abstract]   [Full Text] [Related]  

  • 6. Endothelial dysfunction as a determinant of trastuzumab-mediated cardiotoxicity in patients with breast cancer.
    Sandoo A; Kitas GD; Carmichael AR
    Anticancer Res; 2014 Mar; 34(3):1147-51. PubMed ID: 24596352
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Herceptin and early breast cancer: a moment for caution.
    Lancet; 2005 Nov; 366(9498):1673. PubMed ID: 16291043
    [No Abstract]   [Full Text] [Related]  

  • 8. Cardiotoxicity associated with trastuzumab and chemotherapy used for HER2-positive cancers.
    Mardis C
    MLO Med Lab Obs; 2014 Apr; 46(4):18, 20. PubMed ID: 24783682
    [No Abstract]   [Full Text] [Related]  

  • 9. Perineal reconstruction in the UK: An internet survey.
    Cubitt J; Cogswell L; Drew P
    J Plast Reconstr Aesthet Surg; 2015 Aug; 68(8):1165. PubMed ID: 25986417
    [No Abstract]   [Full Text] [Related]  

  • 10. Barriers, beliefs and practice patterns for breast cancer reconstruction: A provincial survey.
    Coroneos CJ; Roth-Albin K; Rai AS; Rai AS; Voineskos SH; Brouwers MC; Avram R; Heller B
    Breast; 2017 Apr; 32():60-65. PubMed ID: 28038321
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cardiotoxicity associated with trastuzumab (Herceptin) therapy in the treatment of metastatic breast cancer.
    Suter TM; Cook-Bruns N; Barton C
    Breast; 2004 Jun; 13(3):173-83. PubMed ID: 15177418
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Catching broken hearts: pre-clinical detection of doxorubicin and trastuzumab mediated cardiac dysfunction in the breast cancer setting.
    Saeed MF; Premecz S; Goyal V; Singal PK; Jassal DS
    Can J Physiol Pharmacol; 2014 Jul; 92(7):546-50. PubMed ID: 24959994
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High-sensitivity C-reactive protein (hs-CRP) as a biomarker for trastuzumab-induced cardiotoxicity in HER2-positive early-stage breast cancer: a pilot study.
    Onitilo AA; Engel JM; Stankowski RV; Liang H; Berg RL; Doi SA
    Breast Cancer Res Treat; 2012 Jul; 134(1):291-8. PubMed ID: 22476854
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Detection of subclinical trastuzumab-induced cardiotoxicity in patients with breast cancer.
    Santos MH
    Arq Bras Cardiol; 2013 Jul; 101(1):2-3. PubMed ID: 23917505
    [No Abstract]   [Full Text] [Related]  

  • 15. Cardiotoxicity associated with the use of trastuzumab in breast cancer patients.
    Perik PJ; de Korte MA; van Veldhuisen DJ; Gietema JA; Sleijfer DT; de Vries EG
    Expert Rev Anticancer Ther; 2007 Dec; 7(12):1763-71. PubMed ID: 18062750
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Subcutaneous trastuzumab (Herceptin). Ready to use, but more serious adverse effects than intravenous (IV) trastuzumab.
    Prescrire Int; 2015 Apr; 24(159):93. PubMed ID: 25941697
    [No Abstract]   [Full Text] [Related]  

  • 17. Variation in early breast cancer systemic adjuvant therapy practice among UK oncologists with potential impact on patient benefit and the financial burden: national postal questionnaire survey.
    Moe MM
    Clin Oncol (R Coll Radiol); 2009 Nov; 21(9):734-5. PubMed ID: 19656666
    [No Abstract]   [Full Text] [Related]  

  • 18. Trastuzumab-related cardiotoxicity: calling into question the concept of reversibility.
    Telli ML; Hunt SA; Carlson RW; Guardino AE
    J Clin Oncol; 2007 Aug; 25(23):3525-33. PubMed ID: 17687157
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Trastuzumab cardiotoxicity in patients with breast cancer.
    Freitas AF; Rassi S
    Arq Bras Cardiol; 2014 Feb; 102(2):200. PubMed ID: 24676377
    [No Abstract]   [Full Text] [Related]  

  • 20. Monitoring Trastuzumab Resistance and Cardiotoxicity: A Tale of Personalized Medicine.
    Dokmanovic M; Wu WJ
    Adv Clin Chem; 2015; 70():95-130. PubMed ID: 26231486
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.